NuVasive Inc

NuVasive — Q4 2016 Earnings Presentation

15 slides from NuVasive's earnings presentation, Feb 9, 2017

  1. Slide 1: Q4/Full Year 2016 Results Supplemental Presentation to Earnings Press Release

    Q4/Full Year 2016 Results Supplemental Presentation to Earnings Press Release February 9, 2017 Exhibit 99.2

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements NuVasive cautions you that statements included in this presentation that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could caus

  3. Slide 3: Non-GAAP Financial Measures

    Non-GAAP Financial Measures Management uses certain non-GAAP financial measures such as non-GAAP earnings per share, non-GAAP net income, non-GAAP operating expenses and non-GAAP operating profit margin, which exclude amortization of intangible assets, non-cash purchase accounting adjustments on acq

  4. Slide 4: Q4 & Full Year 2016 Performance

    Q4 & Full Year 2016 Performance Reported year-over-year revenue growth of 25.9% to $271.1 million, or 25.5% on a constant currency basis. Delivered GAAP operating profit margin of 11.1%; non-GAAP operating profit margin of 18.0%, up 90 bps from prior year. Drove GAAP diluted earnings per share of $0

  5. Slide 5: Fourth Quarter 2016 Revenue Highlights

    Fourth Quarter 2016 Revenue Highlights 22% U.S. SPINAL HARDWARE Includes All Implants, Fixation, MAGEC® & PRECICE® 26% 42%* * Constant currency basis U.S. SURGICAL SUPPORT Includes Biologics, IOM Services & Disposables INTERNATIONAL Includes Puerto Rico Key Performance Factors Continued Adoption of

  6. Slide 6: NUVA 2016 Highlights

    PROFITABILITY STRATEGY CAPITAL DEPLOYMENT New state-of-the-art manufacturing facility online New international headquarters Settled 8 year litigation with Medtronic Improved asset efficiencies Established $150M revolving credit facility Issued $650M Convertible Senior Notes due 2021 Repurchased $339

  7. Slide 7: Q4 & Full Year 2016 P&L Performance

    Q4 & Full Year 2016 P&L Performance OPERATING LEVERAGE STORY CONTINUES TO PLAY OUT 75.3% 76.6% 52.5% 55.5% 4.8% 5.0% 18.0% 16.1% $0.53 $1.66 26.8% 25.2% NON-GAAP MEASURES Gross Margin SM&A R&D Operating Profit Margin EPS Adjusted EBITDA Margin 4Q16 ACTUALS 4Q16 YOY PERFORMANCE FACTORS FY16 ACTUALS F

  8. Slide 8: Strong History of Growth and Profitability

    * NuVasive financial performance guidance as of February 9, 2017. Global Revenue (In Millions) Non-GAAP Operating Profit Margin ~570 Basis Point Improvement $1,065* 11.4% 15.4% 16.1% 17.1%* Strong History of Growth and Profitability DISCIPLINED EXECUTION OF STRATEGY DRIVES EXCEPTIONAL RESULTS

  9. Slide 9: Investment in U.S. Manufacturing

    New ‘all digital’, 180,000 sq. ft. facility is on-line and supporting select implants and instruments Began manufacturing first products out of facility in Q3 2016 Investing ~$45M to construct and equip new facility with state-of-the-art equipment Expect to employ ~300 high-tech positions Further al

  10. Slide 10: Driving ~20% CAGR in Adjusted EBITDA Improvements

    Driving ~20% CAGR in Adjusted EBITDA Improvements * NuVasive financial performance guidance as of February 9, 2017. Incremental focus on improving the working capital profile and CapEx spending will drive incremental gains in the free cash flow profile of the company. Disciplined approach to driving

  11. Slide 11: Driving Improved Tax Rate

    Driving Improved Tax Rate Focused on reducing tax rate through international scale and domestic tax planning Opportunity to drive non-GAAP effective tax rate lower by ~1,400 bps over 5 years. OPERATING IMPROVEMENTS TAKING HOLD Global tax planning initiatives are playing through: International scale

  12. Slide 12: FY17 Guidance

    * NuVasive financial performance guidance as of February 9, 2017; ^Constant currency FY17 Guidance Performance Drivers Revenues As reported ~$1.065B, ~11.7% YoY growth^ ~$61M full year of Biotronic contribution; ~$10M currency headwind U.S. Spinal Hardware U.S. Surgical Support International ~8% YoY

  13. Slide 13: Q1 2017 Performance Expectations

    Q1 2017 $250M Revenue Non-GAAP operating profit margin of 14.1% Q1 2017 Performance Expectations* PERFORMANCE EXPECTATIONS FOR MODELING PURPOSES 3 ~16.4% Reported Ex FX ~6.7% Pro-forma Ex FX Non-GAAP Earnings per share of $0.37 * NuVasive financial performance guidance as of February 9, 2017; growth

  14. Slide 14: Why Invest in NuVasive

    Growing revenues at multiples of market in high single-digit range* Long-term non-GAAP operating profit margins expanding to ~25% and adjusted EBITDA margin to ~32%* Drive change in tax rate from high 30%’s to high 20%’s* Optimizing tax structure to drive EPS growth 2x the rate of revenue growth* Se

  15. Slide 15: Slide 15

NuVasive — Q4 2016 Earnings Presentation on 6ix